Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Bausch Health Companies Inc
(NY:
BHC
)
8.205
-0.065 (-0.79%)
Streaming Delayed Price
Updated: 9:49 AM EDT, Oct 2, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Bausch Health Companies Inc
< Previous
1
2
...
5
6
7
8
9
10
11
12
Next >
BLCO Stock IPO: When Does Bausch + Lomb Go Public? What Is the Bausch + Lomb IPO Price Range?
May 02, 2022
Here's what investors may want to know about the upcoming BLCO stock IPO, as Bausch + Lomb is split off from its parent company this week.
Via
InvestorPlace
The Week Ahead In Biotech (May 1-7): Phathom FDA Decision, Pfizer, Vertex Pharma Lead Earnings News, Ophthalmology Conference Presentations, And More
May 02, 2022
Biotech stocks posted weekly declines yet again in the week ending April 29, taking cues from the weak broader market sentiment. Big pharma earnings, clinical readouts and pipeline updates moved stocks...
Via
Benzinga
Opening Day: Tenon Medical Shares Soar In Market Debut
April 30, 2022
Shares of Tenon Medical soared in their market debut on Wednesday, opening at $22.05 after the medical-device company had priced its IPO at $5 per share. Meanwhile, Belite Bio opened on April 29 at...
Via
Talk Markets
Jim Cramer Says This Stock Is Still Terrific
April 25, 2022
On CNBC’s "Mad Money Lightning Round," Jim Cramer said Tredegar Corporation (NYSE: TG) was terrific at the time it became public, and it is terrific now also.
Via
Benzinga
IPO Market Stalls With Potential Blockbuster Deals Waiting For Rebound
April 07, 2022
Though IPOs in the first quarter plunged to their lowest level in six years, many companies are in the pipeline ready to go public.
Via
Investor's Business Daily
Opening Day: AN2 Therapeutics Rises In Public Debut After Upsized IPO
March 26, 2022
Shares of AN2 Therapeutics rose over 15% in its trading debut on Friday following an upsized initial public offering. This was only the second initial public offering this month, as the IPO market...
Via
Talk Markets
Opening Day: Cannabis Name Akanda Opens Way Above IPO Pricing, Pulls Back
March 19, 2022
On its first trading day, Akanda fell about 65% from its opening price of $30, though that opening price was nearly eight-times its IPO price of $4. Meanwhile, startup Knock scrapped its plans to go...
Via
Talk Markets
Opening Day: New Stock Offerings Slump To Lowest Number In A Decade
March 05, 2022
It was another slow week for IPOs in the U.S. New stock offerings slumped to the lowest number in over a decade last month amid the war in Ukraine and as rising borrowing costs sent share prices...
Via
Talk Markets
Bausch Health Companies Q4 Sales, FY22 Outlook Lag Wall Street View
February 23, 2022
Bausch Health Companies Inc (NYSE: BHC) has reported Q4 revenues of $2.19 billion, down 1% Y/Y, missing the consensus of $2.80 billion. Excluding the impact of foreign...
Via
Benzinga
Bausch Health Companies: Q4 Earnings Insights
February 23, 2022
Bausch Health Companies (NYSE:BHC) reported its Q4 earnings results on Wednesday, February 23, 2022 at 07:00 AM. Here's what investors need to know about the...
Via
Benzinga
The Daily Biotech Pulse: Kodiak Sinks On Adverse Study Outcome, Marinus Flags Delay In Clinical Trial, Mainz Biomed Gains On Positive Regulatory Development
February 23, 2022
Here's a roundup of top developments in the biotech space over the last 24 hours. Stocks In Focus Kodiak's Wet AMD Treatment KSI-301 Did Not Meet Primary Endpoint In Phase...
Via
Benzinga
Recap: Bausch Health Companies Q4 Earnings
February 23, 2022
Bausch Health Companies (NYSE:BHC) reported its Q4 earnings results on Wednesday, February 23, 2022 at 07:00 AM. Here's what investors need to know about the...
Via
Benzinga
Preview: Bausch Health Companies's Earnings
February 22, 2022
Bausch Health Companies (NYSE:BHC) is set to give its latest quarterly earnings report on Wednesday, 2022-02-23. Here's what investors need to know before the announcement....
Via
Benzinga
Opening Day: Nutraceutical Seller Smart For Life Plunges Following IPO
February 19, 2022
Shares of Smart for Life plunged about 75% following its initial public offering on the Nasdaq. Blue Water Vaccines opened at $50 after having priced its initial public offering of 2.22 million shares...
Via
Talk Markets
The Week Ahead In Biotech (Feb. 20-26): Reata Awaits FDA Decision, Bausch Health, Moderna Lead Earnings News Flow
February 20, 2022
Biotech stock extended lower for a second straight week as risk aversion continued to pressure stocks amid geopolitical tensions and macroeconomic worries. On the regulatory front...
Via
Benzinga
Why The Justice Department Is Going After Short Sellers
February 17, 2022
Federal prosecutors are reportedly ramping up a probe into the activities of short sellers, serving subpoenas and seizing hard drives and mobile phones of prominent "activist...
Via
Benzinga
Two Insider Moonshots Rising on Sudden Buying
February 10, 2022
Biotech insiders are among the most important investors to pay close attention to. Here are two that show good signs for the future.
Via
InvestorPlace
Jim Cramer Buys The Dip In Salesforce, Marvell And This Health Stock
January 21, 2022
With the markets falling further into correction territory, Jim Cramer decided to start adding to some of the positions in hi...
Via
Benzinga
Bausch Health's Eye-Care Spin-Off Entity Files For $100M IPO
January 14, 2022
Bausch & Lomb Corp filed S-1 for its initial public offering, nearly 1.5 years after its parent company, Bausch Health Companies Inc (NYSE: BHC) said it would...
Via
Benzinga
The Daily Biotech Pulse: Bausch Files For Eye Health Unit IPO, LumiraDx Antigen Test Can Detect Omicron, Molecular Partners Discloses Fund Stake
January 14, 2022
Here's a roundup of top developments in the biotech space over the last 24 hours. Stocks In Focus Corvus Says Chinese Angel Pharma Starts Phase 1/2 Blood Cancer Study Corvus...
Via
Benzinga
Jim Cramer's Top Stocks For 2022: Eli Lilly, Honeywell And More
January 05, 2022
Jim Cramer announced his top stock picks for 2022 Wednesday on CNBC's "Fast Money Halftime Report." The fo...
Via
Benzinga
Stock Market Crash Coming? 7 Wall Street Pros Make Their Predictions
December 29, 2021
December is when analysts and banks issue their extensive stock market outlook and winning stocks for the new year.
Via
InvestorPlace
BHC Stock: 9 Things to Know as Jim Cramer Buys Bausch Health
December 20, 2021
The Mad Money host announced a new position in Bausch Health amid the spread of the omicron variant. Here's what you should know.
Via
InvestorPlace
4 Stocks Insiders Are Buying
December 03, 2021
When insiders purchase shares, it indicates their confidence in the company's prospects or that they view the stock as a bargain. Either way, t...
Via
Benzinga
Why Did Bausch Health Shares Plunge Today?
November 02, 2021
Bausch Health Companies Inc (NYSE: BHC) reported Q3 revenues of $2.111 billion, down 1% Y/Y, missing the consensus of $2.66 billion. Excluding the impact of foreign...
Via
Benzinga
Bausch Health Companies inc (BHC) Q3 2021 Earnings Call Transcript
November 02, 2021
BHC earnings call for the period ending October 2, 2021.
Via
The Motley Fool
Topics
Earnings
Exposures
Financial
The Week Ahead In Biotech (Oct. 24-30): Eyenovia, ANI Pharma, Clearside Medical FDA Decisions, Merck, Bristol-Myers Squibb Earnings, IPOs And More
October 24, 2021
Biotech stocks posted gains for the second week running, supported by multiple catalysts that included a good start to the big pharma reporting season and broader market strength...
Via
Benzinga
Exposures
Product Safety
The Week Ahead In Biotech (Oct. 31-Nov. 6): Earnings Pick Up Pace, Eton Awaits Seizure Drug Approval, Kidney Conference, More IPOs In The Pipeline
October 31, 2021
Biotech stocks rose a third week running in the week ending Oct. 29 amid positive reaction to earnings. Big pharma earnings were mostly better than expected. Merck & Co, Inc...
Via
Benzinga
The Daily Biotech Pulse: FDA Authorizes Moderna, J&J Booster Shots; Regulatory Approvals For Bristol-Myers Squibb, Sanofi-Regeneron; Ventyx IPO
October 21, 2021
Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus CDC Committee Recommends Approval Of Merck, Pfizer's Pneumococcal Vaccine...
Via
Benzinga
Exposures
Product Safety
Friday Market Coverage
October 08, 2021
New hiring again failed to rise in Sept., the 2nd month in a row which may be good news because it could delay the Fed tapering.
Via
Talk Markets
Topics
Economy
Exposures
Interest Rates
< Previous
1
2
...
5
6
7
8
9
10
11
12
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.